首页> 美国卫生研究院文献>JRSM Cardiovascular Disease >Catheter-based renal denervation for treatment of resistant hypertension
【2h】

Catheter-based renal denervation for treatment of resistant hypertension

机译:基于导管的肾神经支配治疗顽固性高血压

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hypertension is a common disease associated with important cardiovascular complications. Persistent blood pressure of 140/90 or higher despite combined use of a reninangiotensin system blocker, calcium channel blocker and a diuretic at highest tolerated doses constitutes resistant hypertension. Excess sympathetic activity plays an important pathogenic role in resistant hypertension in addition to contributing to the development of metabolic problems, in particular diabetes. Reduction of renal sympathetic activity by percutaneous catheter-based radiofrequency ablation via the renal arteries has been shown in several studies to decrease blood pressure in patients with resistant hypertension, and importantly is largely free of significant complications. However, longer term follow-up is required to confirm both long-term safety and efficacy.
机译:高血压是与重要的心血管并发症相关的常见疾病。尽管将肾血管紧张素系统阻滞剂,钙通道阻滞剂和利尿剂以最高耐受剂量结合使用,但仍能持续产生140/90或更高的血压,构成抗药性高血压。过量的交感神经活动在抵抗性高血压中起着重要的致病作用,除了会导致代谢问题(特别是糖尿病)的发展。多项研究显示,通过基于肾动脉的经皮导管射频消融术可降低肾交感神经活动,从而降低顽固性高血压患者的血压,并且重要的是,该过程基本上没有重大并发症。但是,需要长期随访以确认长期安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号